The DOI matches its Crossref record.
Beta-Glucuronidase-Mediated Drug Release
Abstract
The selective activation of a relatively non-toxic prodrug by an enzyme present only in the tumour should enhance the drug concentration at the tumour site and result in a better anti-tumour effect and a reduction in systemic toxicity as compared to conventional chemotherapy. beta-Glucuronidase is such an enzyme. It is normally expressed in the lysosomes of cells. In larger tumours, however, high levels of the enzyme are present in necrotic areas. Several glucuronide prodrugs have been synthesised that can be activated by beta-glucuronidase. They are relatively non-toxic due to their hydrophilic nature, which prevents them from entering cells and thus from contact with lysosomal beta-glucuronidase. The main problem of glucuronide prodrugs for clinical use is their fast renal clearance. Special attention should be paid to the development of new less hydrophilic prodrugs with slower clearance, as this would result in a prolonged exposure to beta-glucuronidase at the site of the tumour and a reduction of the amount of prodrug needed. A number of interesting anthracyclin-based glucuronide prodrugs have been synthesised and have shown favourable therapeutic effects compared to treatment with the parent drug. The tumoural levels of beta-glucuronidase can even be enhanced by two-step approaches, in which exogenous enzyme is targeted to the tumour by an antibody (ADEPT) or by the gene encoding the enzyme in transduced tumour cells (GDEPT). The ADEPT and GDEPT approaches in combination with glucuronide prodrugs have shown enhanced efficacy in experimental tumour models. Further improvement of ADEPT and GDEPT is warranted to optimise the tumour uptake and retention of antibody-enzyme fusion proteins and the efficiency and safety of current gene delivery methods. In conclusion, it is clear that glucuronide prodrugs hold promise for future use in the treatment of cancer in patients as monotherapy. Enhancement of the therapeutic effects of glucuronide prodrugs, also in patients with small tumour lesions, may possibly be achieved by techniques that target beta-glucuronidase specifically to the site of the tumour.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Antibody–Drug Conjugates: A Comprehensive Review
Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U., & Zhang, J. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0582 · Cited by 787
Prodrug Strategies in Anticancer Chemotherapy
Kratz, F., Müller, I. A., Ryppa, C., & Warnecke, A. (2008) · ChemMedChem · doi:10.1002/cmdc.200700159 · Cited by 486
Linkers Having a Crucial Role in Antibody–Drug Conjugates
Lu, J., Jiang, F., Lu, A., & Zhang, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040561 · Cited by 285
Imai, Y., Tsukahara, S., Asada, S., & Sugimoto, Y. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0078 · Cited by 280
Beaud, D., Tailliez, P., & Anba-Mondoloni, J. (2005) · Microbiology · doi:10.1099/mic.0.27712-0 · Cited by 160
Metadata
- Authors
- Graaf, M., Boven, E., Scheeren, H., Haisma, H., & Pinedo, H.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2002-07-01
- Volume
- 8
- Issue
- 15
- Pages
- 1391-1403
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2168314315
- Cited by
- 158
- References
- 0
- FWCI
- 1.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Beta-Glucuronidase-Mediated Drug Release. https://app.cochat.ai/papers/10.2174/1381612023394485
- The paper
- Graaf, M., Boven, E., Scheeren, H., Haisma, H., & Pinedo, H. (2002). Beta-Glucuronidase-Mediated Drug Release. Current Pharmaceutical Design. https://doi.org/10.2174/1381612023394485
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.